Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
BioVie Inc. logo — Developing innovative therapies for the treatment of neurode...

BioVie Inc.

Developing innovative therapies for the treatment of neurodegenerative conditions and advanced liver disease.

Founded 2013 United States Carson City, United States 17 employees Post-IPO Equity Biotechnology, Health Care +1

General Information

Company Name BioVie Inc.
Founded Year 2013
Location United States Carson City, United States
Employees 17
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with BioVie Inc.. To contact BioVie Inc., visit bioviepharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BioVie Inc. compare?

A PDF of BioVie Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BioVie Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BioVie Inc.

BioVie Inc. is a biotechnology company established in 2013, focusing on developing innovative therapies for the treatment of neurodegenerative conditions and advanced liver disease. The company's slogan, "Developing innovative therapies for the treatment of neurodegenerative conditions and advanced liver disease," aptly encapsulates its core mission. BioVie's strategy revolves around biochemistry, cellular energetics, and neuroprotection, with the aim of exploring the potential of its pipeline molecules to address inflammation, enhance glucose utilization, protect neurons, and facilitate energy transfer within the central nervous system. This approach is anticipated to result in improved memory, movement, and overall brain health. The lead Neuroscience molecule, NE3107, is presently undergoing human clinical studies, focusing on its hypothesized impact on both Alzheimer’s and Parkinson’s. In addition to its neurological pursuits, BioVie is also delving into the realm of cirrhosis studies. The company aspires to alleviate the medical burden on individuals diagnosed with cirrhosis-related ascites by enhancing comfort, reducing the necessity and frequency of medical procedures to drain ascites fluid, and potentially enabling them to spend longer periods outside the hospital. The company's novel formulation of terlipressin, BIV-201, is currently undergoing human clinical trials, with the medication provided as a continuous infusion formulation via a wearable pump, allowing users to engage in daily activities while receiving treatment. As of 21 October 2024, the company received a Post-IPO Equity investment, signaling the continued interest and support from investors in BioVie's endeavors within the biotechnology, health care, and health and wellness industries. With its groundbreaking research and commitment to improving outcomes for individuals with neurodegenerative conditions and advanced liver disease, BioVie is positioned as a promising player in the biopharmaceutical landscape. For more information about BioVie and its ongoing studies, interested parties can refer to the company's website at https://bioviepharma.com/.

Business keywords: Neurology, Therapeutics, Neuroprotection, Alzheimer's, Parkinson's, Cirrhosis, Ascites, Clinical Studies, BioPharma, Innovative Therapy, Memory Improvement, Liver Disease, Scientific Research, Healthcare Innovation

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity Undisclosed -
21 Oct 2024
Grant Undisclosed -
29 Apr 2024
Post IPO Equity Undisclosed -
04 Mar 2024
Post IPO Debt Undisclosed -
01 Dec 2021
Post IPO Equity Undisclosed -
08 Aug 2021
Post IPO Equity Undisclosed -
04 Apr 2017
Seed Undisclosed -
02 Jul 2013

BioVie Inc. Alternatives & Competitors

View All Alternatives
BioVie Inc. vs
Yaqrit
Yaqrit United Kingdom

The Liver Disease Company

Convertible Note
14 employees
Biotechnology, Health Care
BioVie Inc. vs
APRINOIA Therapeutics
APRINOIA Therapeutics

Aprinoia Therapeutics is dedicated to establish a drug discovery and early development company that...

Venture round
24 employees
Biotechnology, Health Care
BioVie Inc. vs
Neurotrope Inc.
Neurotrope Inc. United States

Developing a new approach to combating Alzheimer's disease and other neurodegenerative diseases.

Series A
3 employees
Biotechnology, Health Care
View all alternatives

FAQ About BioVie Inc.

Developing innovative therapies for the treatment of neurodegenerative conditions and advanced liver disease.
BioVie Inc. was founded in 2013.
BioVie Inc. is headquartered in Carson City, United States.
BioVie Inc. operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Neurology, Therapeutics, Neuroprotection and Alzheimer's.
BioVie Inc. has approximately 17 employees.
BioVie Inc. has completed 7 funding rounds. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to BioVie Inc. include Yaqrit, APRINOIA Therapeutics, Neurotrope Inc., IRLAB Therapeutics AB, Re:Cognition Health. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BioVie Inc. and Yaqrit are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BioVie Inc., https://bouncewatch.com/company/biovie-inc, updated 24 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout